Vaxcyte (PCVX) Expected to Release Quarterly Earnings on Wednesday

Vaxcyte (NASDAQ:PCVX) is anticipated to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($2.06) per share and revenue of $12.50 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the previous year, the business earned ($1.04) earnings per share. On average, analysts expect Vaxcyte to post $-8 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Vaxcyte Stock Performance

Shares of Vaxcyte stock opened at $54.08 on Monday. The company’s 50-day moving average price is $53.25 and its two-hundred day moving average price is $54.95. Vaxcyte has a 52 week low of $29.08 and a 52 week high of $65.00. The stock has a market cap of $7.81 billion, a PE ratio of -7.86 and a beta of 1.22.

Insiders Place Their Bets

In related news, CFO Andrew Guggenhime sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $57.28, for a total value of $572,800.00. Following the completion of the sale, the chief financial officer owned 104,395 shares in the company, valued at approximately $5,979,745.60. This represents a 8.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $56.33, for a total transaction of $126,742.50. Following the transaction, the chief operating officer owned 156,760 shares in the company, valued at approximately $8,830,290.80. The trade was a 1.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 91,396 shares of company stock worth $4,975,725. Company insiders own 3.30% of the company’s stock.

Institutional Trading of Vaxcyte

Several hedge funds and other institutional investors have recently modified their holdings of PCVX. Caligan Partners LP acquired a new position in shares of Vaxcyte during the 4th quarter worth $78,660,000. Adage Capital Partners GP L.L.C. lifted its stake in shares of Vaxcyte by 418.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,725,000 shares of the company’s stock valued at $79,592,000 after purchasing an additional 1,392,000 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Vaxcyte by 18.5% in the fourth quarter. Wellington Management Group LLP now owns 5,966,310 shares of the company’s stock worth $275,286,000 after purchasing an additional 933,539 shares in the last quarter. Deep Track Capital LP boosted its holdings in Vaxcyte by 39.5% in the third quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $108,060,000 after purchasing an additional 850,000 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new position in Vaxcyte during the second quarter worth $26,318,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on PCVX. Wall Street Zen downgraded shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Finally, Zacks Research lowered shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.